Furthermore, SCD1 inhibitors or erastin could promote the sensitivity of gemcitabine treatment in pancreatic cancer cells with overexpression of ZNF488 (Fig. 6G, H), indicating that SCD1 inhibitors and erastin are potential drugs when combining with gemcitabine for the treatment of pancreatic cancer patients with highly expressed ZNF488. This evidence concerns the gene ZNF488 and pancreatic neoplasm.